Transparency data

Meeting minutes of the Vaccine Benefit Risk Expert Working Group from the Covid-19 Pandemic - 25 February 2021 to 6 April 2021

Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 25 February 2021 to 6 April 2021.

• From: Medicines and Healthcare products Regulatory Agency and Commission on Human Medicines
• Published: 9 December 2024

Documents

PDF, 238 KB, 10 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 294 KB, 12 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 237 KB, 10 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 331 KB, 11 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 222 KB, 8 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 363 KB, 12 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 259 KB, 9 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 285 KB, 13 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 279 KB, 9 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

As part of our ongoing mission to improve transparency, we are publishing minutes taken from meetings of the Commission on Human Medicines바카라 사이트™ Vaccine Benefit Risk Expert Working Group (VBREWG) between 25 August 2020 and 5 May 2023. The VBREWG meetings focused on evaluating the safety, efficacy, and overall benefits versus risks of vaccines, providing expert advice and recommendations on licensing and regulatory action.  

Under Section 40 and 43 of the Freedom of Information Act respectively, personal data of individuals and commercially sensitive information has been redacted from these minutes.

Published 9 December 2024